SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

    VANCOUVER, May 19 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced that its corporate partner, Boston Scientific
Corporation (NYSE:   BSX) has reported positive outcomes from a substudy of
patients with left main coronary disease who were treated with the TAXUS(R)
Express(2)(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a
substudy of the landmark SYNTAX trial, the first randomized, controlled
clinical trial to compare percutaneous coronary intervention (PCI) using the
TAXUS Stent to coronary artery bypass graft (CABG) surgery in patients with
left main disease and/or significant narrowing of all three coronary arteries
(three-vessel disease). The substudy data were presented by A. Pieter
Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona.
    SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263
patients with left main disease (149 treated with the TAXUS Stent and 114
treated with CABG). It is designed to assess 15-month patency (vessel
openness) and the safety of stents and grafts in this high-risk population; it
includes separate primary endpoints for each treatment arm. For PCI patients,
the primary endpoint is the rate of long-term patency (defined here as (less
than)50% stenosis) of the treated lesion sites. For CABG patients, the primary
endpoint is the ratio of obstructed/occluded grafts (defined here as (greater
than or equal to)50% stenosis) to total placed grafts. Results were presented
separately for each group, and no formal statistical inferences between the
two groups were made due to the different primary endpoints. Results were also
broken out by left main lesion location, including distal and non-distal.
    For those patients receiving a TAXUS Stent, the patency rate for the
treated lesion was 92 percent. Restenosis was more common with distal lesions
(90% patency) compared with non-distal lesions (98% patency). Reported
in-stent late loss was low at 0.2 mm for non-distal lesions. The reported
15-month MACCE rate (all-cause death, stroke, myocardial infarction and
revascularization) for the TAXUS Stent patients was 13 percent, driven
primarily by a nine percent repeat revascularization rate.
    For CABG patients, the overall obstruction/occlusion ratio at 15 months
was 16 percent, with six percent of grafts obstructed in the range of (greater
than or equal to)50% to (less than)100%, and 10 percent of grafts occluded
100%. On a per patient basis, the obstruction/occlusion ratio was 27 percent,
with nine percent of patients having a graft obstructed in the (greater than
or equal to)50% to (less than)100% range and 18 percent of patients having a
graft occluded 100%. The reported MACCE rate for CABG patients at 15 months
was nine percent.
    "The data announced today from SYNTAX-LE MANS will offer important
insights for doctors as they evaluate treatment options for challenging left
main patients," said Keith Dawkins, M.D., Associate Chief Medical Officer of
Boston Scientific. "We are encouraged by the high stent patency rate at 15
months, which increases our confidence in the application of PCI in this
high-risk population. The results support previously announced outcomes with
PCI and CABG in patients with left main disease."
    The safety and effectiveness of the TAXUS Express(2) Stent System have
not been established in patients with left main or three-vessel disease.

    Forward Looking Statements
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K, and our quarterly report for the three months ended March 31, 2009 filed
with the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890